Blood sampling: Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
Study summary
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria for LPS patients cohort:
Men/women older than 18 years old,
Surgery for :
* Localized WD-LPS and DD-LPS, and/or
* WD-LPS or DD-LPS local relapse, and/or
* WD-LPS or DD-LPS distant relapse and/or
* Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent
Inclusion Criteria for healthy subjects cohort:
Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort
Exclusion Criteria:
Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.
Pregnancy and/or feeding
Primary outcome measure(s)
Sensibility and specificity of circulating serine level for LPS diagnosis — At 3 months post surgery Circulating serine level is a quantitative variable evaluated by its concentration
Trial sites (1)
Facility
City
Region
Status
Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier
France
Recruiting
More Institut du Cancer de Montpellier - Val d'Aurelle trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.